Sun Pharma Advanced Research Co (NSE:SPARC) Total Liabilities: ₹8,320 Mil (As of Mar. 2026)


NSE:SPARC Sun Pharma Advanced Research Co Ltd NSE:SPARC
61 GF Score
Price ₹239.37
GF Value ₹4,504.88
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co Total Liabilities?

Sun Pharma Advanced Research Co NSE:SPARC +0.02% 61 Total Liabilities is ₹8,320 Mil as of Mar. 2026. GuruFocus rates NSE:SPARC with a GF Score™ of 61/100 and a GF Value™ of ₹4,504.88 (Possible Value Trap). The stock has 7 warning signs investors should review.

Sun Pharma Advanced Research Co's Total Liabilities for the quarter that ended in Mar. 2026 was ₹8,320 Mil.

Sun Pharma Advanced Research Co's quarterly Total Liabilities declined from Sep. 2025 (₹6,670.80 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹8,320.40 Mil).

Sun Pharma Advanced Research Co's annual Total Liabilities increased from Mar. 2024 (₹3,892.87 Mil) to Mar. 2025 (₹5,524.82 Mil) and increased from Mar. 2025 (₹5,524.82 Mil) to Mar. 2026 (₹8,320.40 Mil).

Sun Pharma Advanced Research Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co Total Liabilities Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,488.57 3,173.51 3,892.87 5,524.82 8,320.40

Sun Pharma Advanced Research Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,524.82 0.00 6,670.80 0.00 8,320.40
NSE:SPARC
61GF Score
Sun Pharma Advanced Research Co Ltd NSE:SPARC
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sun Pharma Advanced Research Co's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7540.9+(16.6+762.9
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8,320

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=21708.6-13388.2
=8,320

Sun Pharma Advanced Research Co's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7540.9+(16.6+762.9
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8,320

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=21708.6-13388.2
=8,320

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹8,320 Mil mean?
Sun Pharma Advanced Research Co (NSE:SPARC) has a Total Liabilities of ₹8,320 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sun Pharma Advanced Research Co and its competitors.
Is Sun Pharma Advanced Research Co's Total Liabilities too high?
Sun Pharma Advanced Research Co's current Total Liabilities is ₹8,320 Mil. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's Total Liabilities compare to ZTS and UTHR?
Sun Pharma Advanced Research Co's Total Liabilities of ₹8,320 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sun Pharma Advanced Research Co and its competitors. Sun Pharma Advanced Research Co's current Total Liabilities is ₹8,320 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (NSE:SPARC) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,504.88, compared to a current price of ₹239.37 — trading 94.7% below its estimated fair value. The current Total Liabilities is ₹8,320 Mil. Sun Pharma Advanced Research Co's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (NSE:SPARC), the current Total Liabilities is ₹8,320 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (NSE:SPARC) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹239.37 is trading 94.7% below its estimated GF Value™ of ₹4,504.88. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for NSE:SPARC:

  • Total Liabilities: ₹8,320 Mil
  • GF Value™: ₹4,504.88 vs. price of ₹239.37 (94.7% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the NSE:SPARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sun Pharma Advanced Research Co Business Description

Other Exchanges 532872:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
61GF Score

Get the complete analysis for NSE:SPARC

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹239.37
Price
₹4,504.88
GF Value